Fig. 3From: Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experienceMigraine-related disability, impact on daily living and quality of life scores at baseline (T0), and at the end of the third (T1) and of the sixth month (T2) of galcanezumab administrationBack to article page